Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lung fields

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Lung fields. Displaying page 1 of 1.
    EudraCT Number: 2019-003916-29 Sponsor Protocol Number: TREASURE Start Date*: 2020-06-25
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: - TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease: a randomized, open-label, multicenter phase II study
    Medical condition: Small cell lung cancer extensive disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016940-38 Sponsor Protocol Number: REO018 Start Date*: 2010-04-26
    Sponsor Name:Oncolytics Biotech Inc.
    Full Title: Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone...
    Medical condition: Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003109-28 Sponsor Protocol Number: ICLA-20-PNE1 Start Date*: 2007-09-28
    Sponsor Name:Arpida AG
    Full Title: Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-as...
    Medical condition: Hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035664 Pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006843-29 Sponsor Protocol Number: CKI-303 Start Date*: 2007-06-13
    Sponsor Name:NovaCardia Inc
    Full Title: A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes ...
    Medical condition: Patients being admitted to hospital with heart failure and volume overload requiring IV therapy after experiencing worsening of renal function.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) PL (Completed) GR (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005045-34 Sponsor Protocol Number: PPCTP/001 Start Date*: 2008-12-15
    Sponsor Name:Profile Pharma Ltd
    Full Title: A double-blind, vehicle-controlled, multi-centre, clinical study to investigate the efficacy and safety of up to 6 months of therapy with inhaled Promixin in the treatment of patients with non-cyst...
    Medical condition: non-CF bronchiectasis (CF = cystic fibrosis)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001407-37 Sponsor Protocol Number: CKI- 301 Start Date*: 2007-06-20
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005920-39 Sponsor Protocol Number: UC-IMM-2106 Start Date*: 2022-07-12
    Sponsor Name:Unicancer
    Full Title: A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT)
    Medical condition: Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously un...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001637-18 Sponsor Protocol Number: CKI- 302 Start Date*: 2006-11-13
    Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
    Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f...
    Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) CZ (Completed) BE (Completed) DK (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002692-33 Sponsor Protocol Number: H6D-MC-LVGY Start Date*: 2006-04-10
    Sponsor Name:Lilly ICOS LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterised by elevation of pulmonary artery pressure and pulmonary vascular resistance, leading to right heart failure ...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000275-16 Sponsor Protocol Number: CT/12.02 Start Date*: 2012-07-24
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A pilot phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment
    Medical condition: Patients with stage IIIB with pleural effusion or stage IV NSCLC with documented disease progression during or after completion of docetaxel-based treatment are eligible for the study.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003605-55 Sponsor Protocol Number: 74556 Start Date*: 2021-01-15
    Sponsor Name:Erasmus MC - University Medical Centre
    Full Title: Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic disease
    Medical condition: Patients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001873-24 Sponsor Protocol Number: H6D-MC-LVIG Start Date*: 2012-01-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A multiple ascending dose study of Tadalafil to assess the pharmacokinetics and safety in a pediatric population with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001352-34 Sponsor Protocol Number: B3271002 Start Date*: 2013-12-18
    Sponsor Name:Pfizer Inc,
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) GR (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001225-33 Sponsor Protocol Number: UC-0105/1401 Start Date*: 2014-07-21
    Sponsor Name:UNICANCER
    Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations.
    Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019053 Hairy cell leukaemia PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071653 Gastrointestinal stromal cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000885-13 Sponsor Protocol Number: UC-0105/1303 Start Date*: 2013-07-31
    Sponsor Name:UNICANCER
    Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug
    Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002227 Anaplastic large cell lymphoma T- and-cell types PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067917 Inflammatory myofibroblastic tumour PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024658 Liver carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001929-32 Sponsor Protocol Number: 2014/2126 Start Date*: 2014-08-25
    Sponsor Name:Gustave Roussy
    Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
    Medical condition: Diffuse Intrinsic Pontine Glioma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2014-003326-41 Sponsor Protocol Number: 200719 Start Date*: 2016-01-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor
    Medical condition: Preterm Labour
    Disease: Version SOC Term Classification Code Term Level
    19.1 10036585 - Pregnancy, puerperium and perinatal conditions 10036600 Premature labour PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000862-49 Sponsor Protocol Number: RG_15-011 Start Date*: 2016-08-22
    Sponsor Name:The University of Birmingham
    Full Title: Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer?
    Medical condition: Early rectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) SE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:06:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA